By Chase Doyle COVID-19 may have caught the world off guard in 2020, but in the 2 years since the pandemic began, several effective monoclonal antibodies and antiviral drugs have emerged to protect the most vulnerable patients. The ASCO Post spoke with Gunjan L. Shah,...
New research has found that the weakened immune systems of patients with lymphoma may improve after they receive a third COVID-19 vaccination. Patients with lymphoma have defects in their immune system that restrict its response to vaccination; despite this, a study...
Black patients with cancer experienced significantly worse outcomes after a COVID-19 diagnosis than non-Hispanic White patients, according to findings published by Fu et al in JAMA Network Open. Investigators from the COVID-19 and Cancer...
A Polish research team used a spectroscopy technique called Raman imaging to conduct a preclinical study of the effect of COVID-19 mRNA (Pfizer/BioNT) vaccine on in vitro glial cells of the brain. Lodz University Research Team The team members include Halina...
By Matthew Stenger In a Canadian population-based study reported in the Journal of Clinical Oncology, Gupta et al found that survivors of childhood, adolescent, and young adult cancers were not at a greater risk of COVID-19 infection or severe complications of...
By Ajay K. Nooka, MD, et al. ABSTRACT PURPOSE Vaccine-induced neutralizing antibodies (nAbs) play a critical role in protection from SARS CoV-2. Patients with B-cell malignancies including myeloma are at increased risk of COVID-19–related mortality and exhibit...
T-cell responses directed against the receptor-binding domain of the SARS–CoV-2 spike protein were associated with protection from SARS–CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood...
Far from being hobbled by fears of COVID-19, patients with lung cancer actually showed less depression and anxiety during the pandemic than their healthy peers, according to results from a new study by Arrato et al published in JNCCN–Journal of the National...
New research published by Shulman et al in JNCCN—Journal of the National Comprehensive Cancer Network confirmed that mRNA vaccines for COVID-19 are just as safe for people with cancer as they are for cancer-free individuals. Researchers from a single institution...
Cancer-killing cells still present 10 years on, with results suggesting therapy is a cure for certain blood cancers By Linda Geddes Two of the first human patients to be treated with a revolutionary therapy that engineers immune cells to target specific types of...
By Matthew Stenger In an Israeli single-institution study reported in The Lancet Oncology, Ligumsky et al found that a booster dose of the SARS–CoV-2 Pfizer-BioNTech BNT162b2 mRNA vaccine given in August or September 2021 was immunogenic in patients receiving...
Recently, oncologists from a network of oncology center-based care and research centers including the Dana-Farber Cancer Institute and Vanderbilt University, and others report that people with cancer who are fully vaccinated against COVID-19 still face...
By A.L.Schmidt Highlights • Patients with cancer who develop breakthrough COVID-19 following full vaccination remain susceptible to severe outcomes. •Hematologic malignancies are over-represented among vaccinated patients with cancer who develop breakthrough COVID-19....
By Matthew Stenger In a U.S. cohort study reported in JAMA Network Open, Wang et al found that fully vaccinated patients with multiple myeloma were at increased risk of breakthrough SARS–CoV-2 infection, and that those with breakthrough infection were more likely...
By Matthew Stenger In a single-institution Israeli study reported in a research letter in JAMA Oncology, Rottenberg et al found that a booster dose of the SARS–CoV-2 BNT162b2 mRNA resulted in increased spike protein antibody titers in patients with solid tumors...